이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas (XANTHOS)

2026년 8월 2일 업데이트: National Cancer Center, Japan
This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic carcinoma who have a history of platinum-based combination chemotherapy.

연구 개요

상태

아직 모집하지 않음

연구 유형

중재적

등록 (추정된)

35

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Kanagawa
      • Yokohama, Kanagawa, 일본
        • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
        • 연락하다:
          • Shuji Murakami
          • 전화번호: +81-45-520-2222
    • Osaka
      • Chuo-ku, Osaka, 일본
        • Osaka International Cancer Institute
        • 연락하다:
          • Motohiro Tamiya
          • 전화번호: +81-6-6945-1181
    • Tokyo
      • Chuo-ku, Tokyo, 일본, 104-0045
        • National Cancer Center Hospital
        • 연락하다:
          • Yusuke Okuma, M.D., Ph.D.
          • 전화번호: +81-3-3542-2511

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Pathologically diagnosed (histological or cytological examination) as thymic carcinoma originating in the thymus or from a metastatic site Immunohistochemical staining including diagnostic marker testing is recommended. If performed prior to registration, the timing is not restricted. However, if histological examination was conducted at another institution, the pathological diagnosis must generally be obtained by a pathologist at the study site, e.g., by requesting the pathological specimen.)
  2. Meets any of the following criteria:

    1. Thymic carcinoma was classified as Stage IV by the Masaoka-Koga staging at initial diagnosis
    2. Thymic carcinoma was classified as Stage III by the Masaoka-Koga staging at initial diagnosis and was judged to be unresectable with curative resection
    3. The disease is a postoperative recurrence of thymic carcinoma
  3. The patients do not have symptomatic brain metastases, carcinomatous meningitis, or spinal metastases requiring radiation therapy or surgical intervention
  4. The patients do not have pericardial effusion, pleural effusion, or ascites requiring treatment
  5. Age ≥ 18 years at registration
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  7. At least one measurable lesion on contrast-enhanced CT (brain, neck, chest, abdomen, pelvis: slice thickness ≤ 5 mm) performed within 14 days prior to registration (same day of the week 2 weeks prior to registration date is acceptable; same applies below)
  8. History of combination chemotherapy including platinum agents for unresectable thymic carcinoma (treatment in this study will be second-line or later)
  9. No administration of anticancer drugs (chemotherapy, molecularly targeted therapy, immunotherapy, etc.) or other investigational drugs within 28 days prior to the registration date (same day of the week 4 weeks prior to registration date is acceptable; same applies below)
  10. No surgery under general anesthesia within 28 days prior to the registration date
  11. No radiation therapy (including gamma knife, cyberknife) within 14 days prior to the registration date
  12. Laboratory tests performed within 14 days prior to the registration date meet the following criteria #1 to #8. However, no administration of granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days prior to the blood draw date

    1. Neutrophil count ≥ 1,500/mm³
    2. Platelet count ≥ 10 × 10⁴/mm³
    3. Hemoglobin ≥ 9.0 g/dL
    4. AST ≤ 75 U/L (up to 150 U/L allowed if liver metastases are present)
    5. ALT ≤ 75 U/L (up to 150 U/L allowed if liver metastases are present)
    6. Total bilirubin ≤ 1.5 mg/dL
    7. PT-INR ≤ 1.5
    8. Creatinine ≤ 1.5 mg/dL (If creatinine > 1.5 mg/dL, eligibility is confirmed if creatinine clearance (CrCl)* ≥ 30 mL/min) *CrCl is calculated using the Cockcroft-Gault formula: [[140-age (years)] × weight (kg)] / [72 × serum creatinine (mg/dL) × 0.85 (for females)]. Alternatively, CrCl may be measured from a 24-hour urine collection.
  13. Percutaneous oxygen saturation (SpO2) ≥ 92% under room air within 14 days prior to registration date
  14. Patients with adverse events from prior anticancer therapy must have recovered to Grade 1 or below or to baseline values (excluding alopecia and leukoplakia). If endocrine-related adverse events are present, they must be adequately managed with hormone replacement therapy.
  15. For males: Agree to the following for at least 120 days after the last dose of study drug:

    Refrain from sperm donation Use condoms during sexual intercourse with non-study participants of childbearing potential, and have the partner use an additional contraceptive method as described in the Appendix 18.2

  16. For females: Not pregnant or breastfeeding, and meeting at least one of the following conditions:

    1. The patients do not fall under the definition of a woman of childbearing potential (POCBP, Appendix 18.2)
    2. Falls under the definition of a woman of childbearing potential and has agreed to the following:

    For at least 210 days from consent to the final study drug administration, use a highly effective (failure rate <1% per year) and low user-dependent contraceptive method as listed in the Appendix 18.2, or have permanently and continuously abstained from penile-vaginal intercourse as a preferred and habitual lifestyle. During this period, the patient agrees not to donate or freeze/store eggs (ova, oocytes) to others. The period required to maintain contraception for the study treatment is from day 0 (final dose) to day 210. The investigator will assess compliance with the contraception requirements (Appendix 18.2) prior to the first study drug dose.

    A negative pregnancy test must be confirmed using either a urine hCG pregnancy test within 14 days prior to the date of enrollment Refer to Appendix 18.2 for additional requirements regarding pregnancy testing during and after study treatment.

    To reduce the risk of including women with very early, undetected pregnancies, the investigator is responsible for confirming the patient's medical history, menstrual history, and recent sexual activity.

    For lactating patients, they must agree not to breastfeed for at least 10 days after the final study drug dose.

  17. Written informed consent for study participation has been obtained from the patient.
  18. Patients who have undergone cancer genomic profiling testing and have agreed to provide their C-CAT ID (limited to patients registered within Japan). For patients enrolled in South Korea, genomic profiling results, if available, may be provided for supplementary analyses.

Exclusion Criteria:

  1. Patients with thymoma and immune complications associated with thymoma (such as myasthenia gravis, aplastic anemia, hypogammaglobulinemia (Good syndrome), etc.)
  2. Patients with intestinal paralysis or intestinal obstruction
  3. Patients with a history of severe dry eye syndrome, severe meibomian gland disease, or severe corneal disease (impeding or delaying corneal healing)
  4. Uncontrolled major cardiovascular or cerebrovascular disease (NYHA Class III or IV heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, QTcF interval >480 ms, or other major cardiovascular or cerebrovascular disease within 6 months prior to enrollment
  5. Patients with unresolved stomatitis greater than Grade 1 at the time of registration are excluded. Prophylactic supportive care measures for stomatitis are permitted, provided there are no active stomatitis-related symptoms.
  6. Previous treatment history with a TROP2-targeted ADC (such as sacituzumab govitecan)
  7. Previous treatment history with topoisomerase I inhibitors (irinotecan, topotecan) or ADCs containing topoisomerase I inhibitors (e.g., trastuzumab deruxtecan)
  8. Received a live or live-attenuated vaccine within 30 days prior to the registration date. Inactivated vaccines may be administered.
  9. Currently receiving a strong CYP3A4 inducer/inhibitor (Appendix 18.4) that cannot be discontinued during the treatment period of the protocol treatment. The required washout period prior to the registration date is 14 days.
  10. Known malignancy that has progressed or required active treatment within the past 3 years.

    Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (except carcinoma in situ of the bladder) who have undergone curative resection are not excluded.

    Note: Untreated patients with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤ 6, PSA < 10 ng/mL) who have undergone curative treatment or whose disease is stable under active surveillance are not excluded.

  11. Active infection requiring systemic therapy.
  12. Positive for HIV antibody, HBs antigen, or HCV-RNA (HCV-RNA measured only if HCV antibody is positive).
  13. HBs antigen negative, HBs antibody or HBc antibody positive, and HBV-DNA quantitative positive (not excluded if below detection limit).
  14. Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the investigator or sub-investigator.
  15. Has a history of severe hypersensitivity (Grade 3 or higher) to the study drug, its excipients, or other biological therapies.
  16. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: sacituzumab tirumotecan
Sacituzumab tirumotecan at 4 mg/kg is administered intravenously on Day 1 and Day 15 of each 28-day cycle and continued until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria are met. The maximum exposure period for sacituzumab tirumotecan is 78 cycles (approximately 3 years).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective response rate based on central image review
기간: Baseline up to 3 years. Overall Response is assessed every 8 weeks until 24 weeks after initiation of protocol treatment, and every 12 weeks after 25 weeks and after termination. It continues until PD confirmation or post-study treatment initiation.
The primary endpoint is the objective response rate based on central image review. It is defined as the proportion of patients in the FAS who achieved either a CR or PR based on the best overall response determined by central imaging review.
Baseline up to 3 years. Overall Response is assessed every 8 weeks until 24 weeks after initiation of protocol treatment, and every 12 weeks after 25 weeks and after termination. It continues until PD confirmation or post-study treatment initiation.

2차 결과 측정

결과 측정
측정값 설명
기간
Objective response rate based on investigator assessment
기간: Baseline up to 3 years. Overall Response is assessed every 8 weeks until 24 weeks after initiation of protocol treatment, and every 12 weeks after 25 weeks and after termination. It continues until PD confirmation or post-study treatment initiation.
The proportion of patients in the FAS group whose best overall response, as assessed by the treating physician at each study site, is either CR or PR.
Baseline up to 3 years. Overall Response is assessed every 8 weeks until 24 weeks after initiation of protocol treatment, and every 12 weeks after 25 weeks and after termination. It continues until PD confirmation or post-study treatment initiation.
Progression-free survival
기간: From date of enrollment until disease progression or death, whichever occurs first, through study completion, approximately 3 years.
The period from the registration date to the earlier of the date of progression or the date of death from any cause. Note that PD based on imaging studies will use the institution's assessment.
From date of enrollment until disease progression or death, whichever occurs first, through study completion, approximately 3 years.
Overall survival
기간: From date of enrollment until death, through study completion, approximately 3 years.
The period from the registration date to the date of death from any cause is considered overall survival.
From date of enrollment until death, through study completion, approximately 3 years.
Duration of response
기간: From date of enrollment until death, through study completion, approximately 3 years.
The period from the date of initial PR/CR confirmation based on imaging assessment to the earlier of the date of confirmed disease progression or the date of death from any cause. The date of PR/CR confirmation is defined as the first day on which confirmed PR/CR was observed. Definitions for progression and discontinuation are the same as those used for progression-free survival.
From date of enrollment until death, through study completion, approximately 3 years.
Disease control rate
기간: From date of enrollment until disease progression, initiation of post-study treatment, or study completion, approximately 3 years.
The proportion of patients among those with FAS whose best overall response, as determined by central imaging review and institutional assessment, was CR, PR, or SD.
From date of enrollment until disease progression, initiation of post-study treatment, or study completion, approximately 3 years.
Incidence rate of adverse events/incidence rate of adverse reactions
기간: From date of enrollment until death, through study completion, approximately 3 years.
The proportion of patients with each adverse event/adverse reaction among those with SAS. The frequency of the worst grade according to CTCAE v5.0 is calculated for each adverse event/adverse reaction.
From date of enrollment until death, through study completion, approximately 3 years.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 2월 1일

기본 완료 (추정된)

2029년 12월 1일

연구 완료 (추정된)

2030년 6월 1일

연구 등록 날짜

최초 제출

2026년 8월 2일

QC 기준을 충족하는 최초 제출

2026년 8월 2일

처음 게시됨 (실제)

2026년 8월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 2일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다